Seeking Alpha
View as an RSS Feed

Eric Wick  

View Eric Wick's Comments BY TICKER:
Latest  |  Highest rated
  • Pluristem's Positive Data Could Open Massive Muscle Injury Market [View article]
    Thank you very much for the insightful and informative article Sharon. In 2012 Pluristem projected the public data release on this study for late Q1 2013. It's always good to see a developmental company that is eager to publicize it's data earlier than they originally promised. Positive data could be monumental for Pluristem's future in the growing muscle injury market. Exciting time!
    Jan 6, 2014. 07:31 PM | 2 Likes Like |Link to Comment
  • Why Has Antares Pharma Fallen So Rapidly? [View article]
    Big money plays the "there will always be a bigger fool game". Rookie investors by nature feel panic in sharp drops and sell off at steep losses. Then the charge up starts again and they buy back in even higher than their original purchase. Its a bio-tech pre-catalyst event phenomena that yields big profits for those with the money to pull it off! Don't be the bigger Fool!
    Sep 19, 2013. 05:33 PM | 5 Likes Like |Link to Comment
  • Why Has Antares Pharma Fallen So Rapidly? [View article]
    I believe this is a classic case of big money playing the "pre-event" profit game by selling out large positions, shaking weak investors out, then buying more big blocks at a lower price. Before Oct. 10, I would not be at all surprised to see another run-up to $4.75, then another big sell off right before announcement. FDA Approval is NEVER a guarantee! I however share your opinion that ATRS will get Otrexup approved on Oct10. Those who can sweat out these pre-event trading games will be rewarded after Oct. 10. Good luck!
    Sep 19, 2013. 05:29 PM | 4 Likes Like |Link to Comment
  • The Bull Case For Pluristem Therapeutics [View article]
    Thanks for the article Kanak. You present some solid points on the bull case for PSTI. I'm a little surprised that you left out the major significance of the agreement with South Korean Cha Bio&Distech. Once the hold is lifted, assuming it will be, the PPS should appreciate above prior resistence levels of 3.90-4.00.

    Kanak - do you happen to have any insight as to why the updates on the new manufacturing facility ceased? Did the FDA ever recoginize their new facility as a certified GMP mfg facility by USA standards? Also, what are your thoughts as to why no institutions have jumped aboard on PSTI yet?
    Aug 19, 2013. 03:33 PM | 1 Like Like |Link to Comment
  • Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine [View article]
    Very sad day for PSTI shareholders. When all of this negative publicity wears off there will be an excellent buying opportunity. Unfortunately, stock will likely head much further South in the near term as investors will be livid at what's surfacing today. PSTI is going to have to deal with the consequences for their "selective reporting" in this situation. I feel very let down by this companies management.
    Nov 8, 2012. 02:08 PM | 1 Like Like |Link to Comment
  • Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine [View article]
    Sharon, thank you for writing this article, and for bringing to light the significance of Pluristem's proactive efforts in standardizing uniform doses of stem cell treatment. I agree that many have overlooked the importance of this milestone. Here is a link to an article that reiterates the promising future for stem cells that could be banked for off the shelf use. http://yhoo.it/VOU9Zy The stem cells they discuss in this article are far less potent than the fresh placental based cells that PSTI is producing, yet they still show efficacy in restoring heart tissue. PSTI has an exciting future ahead! Glad they are taking the right steps now to avoid future pitfalls in therapy i.e. unpredictable results as a result of unstandardized delivery.
    Nov 5, 2012. 06:18 PM | 2 Likes Like |Link to Comment
  • Curis: A Stock Fueled By Sonic Hedgehog [View article]
    Where are you getting $500 million in sales carsons? Let me spell it out for you here, please read:
    In Missouri's own article written back in April of this year, he wrote that estimated peak sales for Erivedge in Non-Operable BCC alone, which represents a small piece of the total potential for Erivedge are estimated at $1BIL. 7% of 1 BIL is $70MIL. Their annual costs run around $28MIL. = $42MIL in earnings. With an industry average P/E ratio of 15 that gives them a market cap of $675MIL. Market cap $675 MIL/ 80MIL shares outstanding = PPS of $8.44. I estimate CRIS will hit 8.44 well before 2014.
    Oct 23, 2012. 08:58 PM | Likes Like |Link to Comment
  • Curis: A Stock Fueled By Sonic Hedgehog [View article]
    Missouri, in your opinion, if you leave the internal developmental issues aside and focus on the future of Erivedge, do you feel the market has already priced in everything Erivedge has to offer as far as future cash flows to Curis? I understand you have no faith in the ability of management to competently complete internal programs. Holding that aside, considering their current cash position and expected growth of Erivedge, are you 100% convinced this stock is a loser?
    Oct 23, 2012. 08:28 PM | Likes Like |Link to Comment
  • Dilution Is The Solution To Pollution [View article]
    That would be nice :)
    Oct 23, 2012. 11:29 AM | Likes Like |Link to Comment
  • Curis: A Stock Fueled By Sonic Hedgehog [View article]
    Missouri, I appreciate all of the research you've done on Curis over the years. One point I'd like to make is that setbacks in development can also be viewed as management's attempt to slow the cash burn rate and keep the company from having to incur debt. I'm actually satisfied to know that management is willing to "let off the gas pedal" in new drug development in order to be more conservative with cash management. Erivedge has gotten off to a very solid start in the small space that it's currently approved in. As sales begin to expand worldwide, as well as the number of approved indications, royalties will increase rapidly and Curis will soon become cash flow positive. At that point they will have more freedom to decide how aggressively they can be on drugs in development.
    Oct 23, 2012. 11:22 AM | Likes Like |Link to Comment
  • Curis: A Stock Fueled By Sonic Hedgehog [View article]
    George, click on the link I provided in the article for "roche reported YTD sales" then download the "presentation slides with appendix" from that page. You will find a page that specifically reports 44% weekly growth in prescriptions.Easy on the bourbon, scotch and beer, haha, J/K!
    Oct 22, 2012. 02:15 PM | Likes Like |Link to Comment
  • Curis: A Stock Fueled By Sonic Hedgehog [View article]
    Carsons, I believe you may have missed the entire point of my article. Your statement is an opinion shared by many others and it reinforces precisely why I argue that this stock is undervalued. Sales of Erivedge could reach $100M in the US market of advanced, Non-Operable BCC by 2014. Doctors are typically creatures of habit and it takes them some time to start writing scripts for new drugs, yet sales have already hit over $19M for a drug that was just recently launched. That's not even the point I'm trying to make. The point is that:
    The US Market for Non-Operable BCC is a small puddle compared to an OCEAN that is the worldwide market for other cancer indications that Erivedge may be effective for. Compare US advanced basal cell carcinoma to the worldwide market for pancreatic cancer, non-advanced BCC, small-cell lung cancer, breast cancer and others. 7% of billions of dollars can add up to quite a bit, also considering that Curis doesn't incur any operational costs for the marketing or distribution of Erivedge. If you share my opinion that Erivedge may have potential in getting approved for all of these other indications, then you must reconsider where their sales could be five years from now. If you realize the potential after the institutions do, I'm sorry but you will be left behind.
    Oct 22, 2012. 01:11 PM | Likes Like |Link to Comment
  • Curis: A Stock Fueled By Sonic Hedgehog [View article]
    I took that statement directly from the Roche quarterly sales report. I believe they meant the average # of scripts written per week in Q3 was 44% higher than the avg number in Q2.
    Oct 22, 2012. 10:28 AM | Likes Like |Link to Comment
  • Dilution Is The Solution To Pollution [View article]
    jargon, check out this article: http://onforb.es/NgofXK

    Average RA patient is age 60+
    Oct 10, 2012. 05:45 PM | Likes Like |Link to Comment
  • Dilution Is The Solution To Pollution [View article]
    Simply writing to support my long position on atrs and psti. Obamacare = less $$ for medicare patients = less specialist MD's who accept medicare = severely overcrowded general practioner offices = less time for GP's to inject RA patients with MTX + increased desire to write MTX scripts and keep RA patients out of MD office = huge demand for Vibex auto injector (15% market share is too conservative). From the perspective of a long atrs investor, managed care isn't so bad. Insurance companies, who as you mentioned, will have more say in how patients get treated, will also have huge financial incentive to push docs to offer their patients Vibex MTX auto injectors. This is a WIN WIN WIn scenario for atrs, primary care docs, and insurance companies. Only losers are highly trained specialist MD's and implantable device mfg's ie. BSX or MDT, who will be losing $$ on reimbursement and receiving tax hikes.
    Oct 10, 2012. 03:13 PM | Likes Like |Link to Comment
COMMENTS STATS
20 Comments
18 Likes